Nov. 4, 2009 (Business Wire) -- Due to the recent downward pressure on the price of Health Discovery Corporation’s common stock (OTCBB: HDVY) after breaking through multiple 52-week highs in a few short weeks as it did in the past month, the Company has received numerous investor inquiries. Given these inquiries and in order to make Company information available on a uniform basis, the Company would like to provide an intra-quarterly update on its activities, to and including, but not limited to, the following since its most recent quarterly filing:

• The Company’s private placement Series B fund raising is going extremely well and the Company expects to close this round of financing in the next few weeks. These Series B shares are not common shares and are not registered with the Securities and Exchange Commission. We are pleased to announce that many of the participants in this Series B funding round are current shareholders of the Company.
• The Company continues to make great progress on its urine-based prostate cancer test.

As previously announced, HDC recently entered into royalty-bearing licenses for its new urine-based prostate cancer test with Quest Diagnostics Incorporated (NYSE: DGX) and Abbott Laboratories (NYSE: ABT) for development and commercialization. The Company also entered into royalty-bearing licenses for its tissue biopsy-based prostate cancer test with Abbott Laboratories (NYSE: ABT) and Clarient Inc. (NasdaqCM: CLRT) for development and commercialization.

• The Company’s minority-owned subsidiary, Smart Personalized Medicine, LLC, has recently entered into a licensing agreement with a world-renowned international cancer center to develop a breast cancer prognostic test and, with the Company, are currently in discussions with a national clinical laboratory for development and commercialization of the test.
• The Company is finalizing the image processing development on its PAP Smear interpretation test. The Company entered into a development and commercialization agreement with DCL Laboratories for this test as well as tests for ovarian and endometrial cancer.
• Discussions are underway with an international diagnostics company regarding the development and commercialization of the Company’s colon cancer molecular diagnostic test.
• Since the recent press release on the status of the Company’s IP portfolio on October 19, 2009, the United States Patent and Trademark Office has issued additional Notices of Allowance on two of HDC’s patent applications covering the use of SVMs for analysis of spectral data.